Oliveira, Giacomo http://orcid.org/0000-0001-7435-5603
Stromhaug, Kari
Klaeger, Susan http://orcid.org/0000-0002-0074-5163
Kula, Tomasz
Frederick, Dennie T.
Le, Phuong M.
Forman, Juliet
Huang, Teddy
Li, Shuqiang
Zhang, Wandi
Xu, Qikai
Cieri, Nicoletta http://orcid.org/0000-0003-1340-6272
Clauser, Karl R.
Shukla, Sachet A.
Neuberg, Donna http://orcid.org/0000-0003-2566-3145
Justesen, Sune
MacBeath, Gavin http://orcid.org/0000-0003-2585-6772
Carr, Steven A.
Fritsch, Edward F.
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Sade-Feldman, Moshe http://orcid.org/0000-0002-0022-0287
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Boland, Genevieve M.
Ott, Patrick A. http://orcid.org/0000-0002-4253-943X
Keskin, Derin B.
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Article History
Received: 21 December 2020
Accepted: 8 June 2021
First Online: 21 July 2021
Competing interests
: E.F.F. is an equity holder and consultant for BioNTech, and equity holder and SAB member of BioEntre. N.H. and C.J.W. are equity holders of BioNTech. N.H. is an advisor and equity holder for Related Sciences, and receives research funding from Bristol-Myers Squibb. P.A.O. has received research funding from and has advised Neon Therapeutics, Bristol-Myers Squibb, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, Array, AstraZeneca/MedImmune, Armo BioSciences and Roche/Genentech. C.J.W. is subject to a conflict of interest management plan for the reported studies because of her former competing financial interests in Neon Therapeutics, which was acquired by BioNTech. Under this plan, C.J.W. may not access identifiable data for human participants or otherwise participate directly in the IRB-approved protocol reported herein; the contributions by C.J.W. to the overall strategy and data analyses occurred on a de-identified basis. Patent applications have been filed on aspects of the described work entitled as follows: ‘Compositions and methods for personalized neoplasia vaccines’ (N.H., E.F.F. and C.J.W.), ‘Methods for identifying tumour specific neo-antigens’ (N.H. and C.J.W.), ‘Formulations for neoplasia vaccines’ (E.F.F.) and ‘Combination therapy for neoantigen vaccine’ (N.H., C.J.W. and E.F.F.). The Dana-Farber Cancer Institute has a proprietary and financial interest in the personalized NeoAg vaccine. S.J. is chief scientific officer of Immunitrack. S.A.S. reported non-financial support from Bristol-Myers Squibb outside the submitted work, previously advised and has received consulting fees from Neon Therapeutics, and reported non-financial support from Bristol-Myers Squibb and equity in Agenus Inc., Agios Pharmaceuticals, Breakbio Corp., Bristol-Myers Squibb and Lumos Pharma, outside the submitted work. T.K. and G.M. are employees of TScan Therapeutics and hold equity in TScan Therapeutics. T.K. is a founder of TScan Therapeutics. D.B.K. has previously advised Neon Therapeutics and has received consulting fees from Neon Therapeutics, and owns equity in Aduro Biotech, Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Bristol-Myers Squibb, Celldex Therapeutics, Editas Medicine, Exelixis, Gilead Sciences, IMV, Lexicon Pharmaceuticals, Moderna and Regeneron Pharmaceuticals. BeiGene, a Chinese biotech company, supports unrelated research at the DFCI Translational Immunogenomics Laboratory (TIGL). S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs and Seer, and a scientific advisor to Pfizer and Biogen. The remaining authors declare no competing interests.